Literature DB >> 33506944

Does Angiotensin II receptor blockers increase the risk of SARS-CoV-2 infection? A real-life experience.

A De Vito1, N Geremia, E Princic, C Fanelli, C M Panu Napodano, A A Muredda, V Fiore, I Maida, A G Fois, S Babudieri, G Madeddu.   

Abstract

OBJECTIVE: Since the start of the COVID-19 pandemic, millions of people have been infected with thousands of deaths. Few data regarding factors that increase the risk of infection are available. Our study aimed to evaluate all people living in retirement homes (PLRNH) and identify factors that could increase infection risk in a close community.
MATERIALS AND METHODS: We conducted a retrospective study enrolling all PLRNH, where at least one SARS-CoV-2 infected person was present. Variables were compared with Student's t-test or Pearson chi-square test as appropriate. Uni- and multivariate analyses were conducted to evaluate variables' influence on the infection.
RESULTS: We included 452 PLRNH; 144 (31.7%) were male, with a mean age of 82.2±8.6 years. People with a positive swab for SARS-CoV-2 were 306 (67.4%). A significant difference between SARS-CoV-2 infected and not infected was observed in the percentage of those receiving chronic treatment with Angiotensin II receptor blockers (ARBs) (18.6% vs. 9.5%, p=0.012). On the contrary, there was no difference in the proportion of those receiving ACE inhibitors (ACE-I) (21.2% vs. 23.6%, p=0.562). At multivariate analysis, people with mental illness and cancer had an increased risk of being infected. Furthermore, receiving ARBs as a chronic treatment was an independent predictor of infection risk [OR 1.95 (95% CI 1.03-3.72) p=0.041].
CONCLUSIONS: Our data suggest that, in close communities, such as retirement nursing homes, the receipt of ARBs increased the risk of acquiring SARS-CoV-2 infection. However, before changing an important chronic treatment in a fragile population, such as the elderly living in retirement nursing homes, clinicians should carefully evaluate the risk-benefit ratio.

Entities:  

Year:  2021        PMID: 33506944     DOI: 10.26355/eurrev_202101_24424

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

1.  Mood Reactive Disorders among COVID-19 Inpatients: Experience from a Monocentric Cohort.

Authors:  Vito Fiore; Andrea De Vito; Chiara Fanelli; Nicholas Geremia; Elija Princic; Alessandra Nivoli; Ivana Maida; Liliana Lorettu; Giordano Madeddu; Sergio Babudieri
Journal:  Med Princ Pract       Date:  2021-09-28       Impact factor: 1.927

Review 2.  Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.

Authors:  Jordan Loader; Frances C Taylor; Erik Lampa; Johan Sundström
Journal:  J Am Heart Assoc       Date:  2022-05-27       Impact factor: 6.106

Review 3.  Protective role of vitamin D status against COVID-19: a mini-review.

Authors:  Maryam Vasheghani; Mahsa Rekabi; Makan Sadr
Journal:  Endocrine       Date:  2022-10-18       Impact factor: 3.925

4.  Effectiveness of Vitamin D Supplements among Patients Hospitalized for COVID-19: Results from a Monocentric Matched-Cohort Study.

Authors:  Vito Fiore; Andrea De Vito; Paola Bagella; Elija Princic; Anna Antonella Mariani; Lucia Denti; Alessandro Giuseppe Fois; Giordano Madeddu; Sergio Babudieri; Ivana Maida
Journal:  Healthcare (Basel)       Date:  2022-05-22

5.  Predictors of the prolonged recovery period in COVID-19 patients: a cross-sectional study.

Authors:  SeyedAhmad SeyedAlinaghi; Ladan Abbasian; Mohammad Solduzian; Niloofar Ayoobi Yazdi; Fatemeh Jafari; Alireza Adibimehr; Aazam Farahani; Arezoo Salami Khaneshan; Parvaneh Ebrahimi Alavijeh; Zahra Jahani; Elnaz Karimian; Zahra Ahmadinejad; Hossein Khalili; Arash Seifi; Fereshteh Ghiasvand; Sara Ghaderkhani; Mehrnaz Rasoolinejad
Journal:  Eur J Med Res       Date:  2021-05-06       Impact factor: 2.175

Review 6.  Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection.

Authors:  Mostafa Akbarzadeh-Khiavi; Mitra Torabi; Leila Rahbarnia; Azam Safary
Journal:  Infection       Date:  2021-12-13       Impact factor: 7.455

7.  Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review.

Authors:  Jingwei Li; Yali Wang; Yong Liu; Ziqu Zhang; Yuyun Zhai; Yan Dai; Zijian Wu; Xiang Nie; Lunfei Du
Journal:  Eur J Med Res       Date:  2022-02-22       Impact factor: 2.175

8.  Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience.

Authors:  Andrea De Vito; Agnese Colpani; Alessandra Bitti; Beatrice Zauli; Maria Chiara Meloni; Marco Fois; Lucia Denti; Sara Bacciu; Claudia Marcia; Ivana Maida; Sergio Babudieri; Giordano Madeddu
Journal:  J Med Virol       Date:  2022-08-02       Impact factor: 20.693

9.  Emerging Clinical Features of COVID-19 Related Pancreatitis: Case Reports and Review of the Literature.

Authors:  Vito Fiore; Rosalba Beretta; Andrea De Vito; Aleksandra Barac; Ivana Maida; David David Joeseph Kelvin; Claudia Piu; Vincenzo Lai; Giordano Madeddu; Salvatore Rubino; Goran Stevanovic; Stefan Korica; Sergio Babudieri
Journal:  Front Med (Lausanne)       Date:  2022-01-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.